Dymension is being used at the Open Mind Institute (OMI), Slovenia, a centre for studying the effects of medicinal plants, to determine the effects of the anti-addictive alkaloid ibogaine on the brain
Researchers in the OMI in collaboration with scientists at the University of Ljubljana in Slovenia are using Dymension to accurately determine any post ibogaine treatment differences in silver stained rat brain proteins run on 2D gels.
The protein profiles are used to establish which proteins are up or down-regulated.
This research could lead to a better understanding of the pharmacodynamics of anti-addiction therapies.
Roman Paskulin, director of the OMI explained: "We are relatively new to proteomic analysis so we chose to install Dymension software because we want to rapidly perform complicated analysis, and of the software packages we reviewed, this was visually easier to navigate and simpler for everyone to use".
Paskulin added: "Using Dymension to analyse our 2D gel images in association with Maldi-Tof on the resulting protein spots, we have seen increases in four metabolic enzymes after ibogaine treatment and are now looking at the significance of these findings".
Laura Sullivan, Syngene's divisional manager, said: "We are delighted to see our Dymension software being used to accelerate the pace of such interesting research.
"The software has enabled scientists at the OMI and the University of Ljubljana to analyse their 2D gel results so rapidly they have already published a paper and is a testament to how quick and simple it is to integrate and work with Dymension software in any proteomics project."
